NCT00168766 - Avonex (Interferon-beta-1a) and Avonex Plus Methylprednisolone for the Treatment of Relapsing-remitting MS | Biotech Hunter

Enrollment

345

Participants

Timeline

Start Date

January 31, 2003

Primary Completion Date

November 30, 2008

Study Completion Date

November 30, 2008

Conditions

Relapsing-remitting Multiple Sclerosis

Interventions

DRUG

Interferon-beta-1a (Avonex) plus methylprednisolone

oral administration given on 3 consecutive days, monthly as described in protocol.

Trial Locations (9)

CUB Hôpital Erasme, Brussels

Coordinating Research Site, Copenhagen

Rigshospitalet, Skleroseklinikken

Tampereen yliopistollinen sairaala - Neurologian klinikka, Tampere

Stichting MS Centrum, Nijemegen

Ullevål Universitetssykehus, Oslo

Neurologkliniken, Stockholm

Kantonspital, Sankt Gallen

Queens Medical Centre - Division of Neurology, Nottingham